The Department of Health and Human Services, through the National Institutes of Health (NIH) and its National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), has announced a funding opportunity for clinical trial implementation via a two-phase cooperative agreement (UG3/UH3). This funding seeks applications for interventional clinical trials that are ready to move forward after necessary preparatory work has been carried out. The UG3 phase supports activities needed to finalize trial design and logistics, while the UH3 phase involves the full execution and assessment of the trial. Key requirements include clear milestone achievement for progression from UG3 to UH3, a focus on clinical impact within NIAMS missions, and the necessity for participant engagement, particularly from underserved populations. Applications with budgets limited to $250,000 for UG3 and up to five years for the UH3 phase can be submitted through Grants.gov, with detailed project timelines and milestones as essential components. The emphasis on collaboration with lived experience representatives underscores a commitment to health equity and inclusive research practices. The anticipated funding awards depend on project viability and scientific merit, promoting innovative approaches in clinical studies targeting arthritis and related disorders.